Huntington's disease

MMJ International Asks FDA to Approve Studies of Cannabis-based Therapies

MMJ International has filed two applications with the U.S. Food and Drug Administration (FDA) requesting permission to begin clinical studies testing its pharmaceutical grade cannabis-based therapies in easing symptoms associated with multiple sclerosis and Huntingtonā€™s disease. ā€œThe filing of these applications with the FDA brings us one step…

Mitochon Raises $1.6M to Begin Clinical Tests of Mitochondrial Modulators for MS

Mitochon PharmaceuticalsĀ announced the completionĀ of a second year of financing, raising a total $1.6 million to advance itsĀ lead compound, MP101, a mitochondrial targeted neuro-protective agent, into clinical testing. The company is developingĀ mitochondrial modulators for patients with neurodegenerative diseases ranging from Alzheimer’s and Parkinson’sĀ toĀ multiple sclerosis (MS). A number of studies have…

MS Drug Under Study No Longer Being Given in Higher Doses to Patients

Teva Pharmaceutical Industries Ltd. and Active Biotech have discontinued the use of higher doses of the drug laquinimod in two ongoing multiple sclerosis (MS) studies. The decision was based on a recommendation byĀ the Data Monitoring Committee (DMC)Ā that isĀ supervising the clinical trials afterĀ cardiovascular events, none of which were fatal,…

Teva and Active Biotech Expand Investigational MS Treatment Program

Drug manufacturersĀ Teva Pharmaceutical Industries Ltd.Ā and Active Biotech announced that they expanding the ongoing clinical research program for the study ofĀ laquinimod, a potential treatment for primary progressive multiple sclerosis (PPMS), as the companies are now initiating theĀ ARPEGGIO trial. In addition, Teva has also announced…